Deborah Minor

In drug development, success depends on more than scientific innovation. It depends on having access to the right expertise at the right time. As development programs advance, companies face countless decisions. They must select CROs for preclinical studies, identify CDMOs for manufacturing, engage regulatory consultants, source APIs, and find specialized analytical laboratories. While thousands of organizations offer these services, identifying the right partner for a specific program is...

In drug development, the next milestone often reveals how strong the current plan really is. A program may appear to be moving forward. Vendors are active, studies are underway, analytical work is progressing, and timelines are being tracked. But as the program gets closer to IND-enabling studies, clinical supply, tech transfer, or later-stage manufacturing, gaps can become more visible. A process that worked at small scale may not be ready for larger batches. An analytical method may need...